Gaithersburg, MD, May 5, 2015 – MaxCyte®, Inc., ‘the pioneer in cell therapies using scalable, highperformance cell transfection systems, will announce at Cambridge Healthtech Institute’s 11th Annual PEGS summit, May 4-7, 2015 in Boston, MA, that it has been able to achieve 2.7 grams/Liter of antibody in CHO cells using MaxCyte’s Flow Electroporation. Data will be shared in a podium presentation by Dr. James Brady showing the use of flow electroporation technology coupled with cell culture optimization to achieve this titer. In addition, the use of this technology to enable research and development with CHO cells for rapid clinical-grade biotherapeutics will be discussed.
“Achieving 2.7 grams/Liter in CHO cells is an extraordinary accomplishment using transient transfection,” said Dr. Brady, Vice President of Technical Applications and Customer Support. “Along with attaining high titers, no other transient transfection system has the scalability, flexibility regarding cell type, and the reproducibility as the MaxCyte Flow Electroporation Systems.”
Details of the MaxCyte presentation are as follows:
Event: PEGS Boston
Title: Optimizing CHO Expression for Rapid Identification of Relevant Drug Candidates with Flow Electroporation
Date: Thursday, May 7, 2015
Time: 3:35 PM
Location: Sea Port World Trade Center, Boston, MA
Along with the podium presentation, MaxCyte will present a scientific poster and have an exhibit booth with the MaxCyte STX® Scalable Transfection System, the MaxCyte VLX® Large Scale Transfection System, and the MaxCyte GT Flow Electroporation System on display. The MaxCyte GT is currently being used in preclinical trials with several institutions for cell-based therapeutics to treat solid tumors. MaxCyte scientists will be available throughout the conference to provide technical details on the operation and use of the instruments for small molecule drug discovery, biotherapeutics, and cell-based medicines.
MaxCyte is a world leader in the discovery, development, manufacture, and delivery of innovative cell-based medicines utilizing its novel best in class cell modification technology. MaxCyte has developed a next-generation technology–MaxCyte GT® Flow Transfection System–for the rapid engineering of human cells as therapeutics, enabling the development of safer, more effective and lower cost cell-based therapies for a broad range of applications with blockbuster commercial potential. The company currently has clinical, pre-clinical-partnered, and proprietary products under development and is presently involved in more than a dozen clinical trials.
MaxCyte’s proprietary CARMA products utilize a universal platform for the rapid loading of messenger RNA encoding for Chimeric Antigen Receptors (CARs) into peripheral blood cells without the need for ex vivo expansion, reducing time, cost, and complexity associated with centralized manufacturing for ex vivo cell expansion-based processes. MaxCyte recently entered into a collaboration with The Johns Hopkins Kimmel Cancer Center to treat solid tumors with its CARMA products.
The MaxCyte GT® Flow Transfection System is a universal platform for the rapid, automated loading of CARmodified mRNA into peripheral blood cells, which avoids the time and cost-intensive cell expansion process. The loading of fresh patient cells with CAR mRNA harnesses immune cells for targeted killing of tumors. This anti-tumor activity is not dependent on the patient’s immune system and is independent of cell surface concentration of the tumor antigen.
The Company also markets a portfolio of products and services that include the MaxCyte STX® Scalable Transfection System and MaxCyte VLX® Large Scale Transfection System. These platforms are used in drug discovery research and screening and protein production environments by 9 of the top 10 pharma companies worldwide as well as the top three in Japan. MaxCyte products enable the rapid development and consistent production of billions of (co)transfected primary cells, stem cells, and cell lines for protein and antibody production, rapid response vaccine development, and for cell-based assays with comparable results and Seamless Scalability™ from the bench to HTS and pilot and production scale.
For more information visit /